

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On August 20

TOWNSEND and TOWNSEND and CREW LLP

By: mtd
Mark T. Davis

IFIAJ
PATENT
Attorney Docket No.: 021288-002920US
Client Reference No.: P1087US40



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NASOFF et al.

Application No.: 10/723,383

Filed: November 25, 2003

For: METHODS AND COMPOSITIONS
FOR INDUCING APOPTOSIS IN
CANCER CELLS

Examiner: Not yet assigned

Art Unit: 1645

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 1287 OG 163] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Matthew E. Hinsch
Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
ASP:mtd
60572900 v1



Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/723,383
				Filing Date	November 25, 2003
				First Named Inventor	Nasoff, Marc
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	021288-002920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	CHUNTHARAPAI, Anan et al.; "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4"; <u>The Journal of Immunology</u> , Vol. 166, pp. 4891-4898.	
	AB	DONG, Qiang G. et al.; "The function of multiple IKB: NF-kB complexes in the resistance of cancer cells to Taxol-induced apoptosis"; 2002, <u>Oncogene</u> , Vol. 21, pp. 6510-6519.	
	AC	ODOUX, Christine et al.; "TrAIL, Fasl and a Blocking Anti-DR5 Antibody Augment Paclitaxel-Induced Apoptosis in Human Non-Small-Cell"; 2002, <u>Int. J. Cancer</u> , Vol. 97, pp. 458-465.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.